search
Back to results

Prophylactic Use of Cranberries in Recurrent Bacterial Cystitis in Women

Primary Purpose

Recurrent Urinary Tract Infections in Women

Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Cysticlean
Placebo
Sponsored by
University of Thessaly
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Recurrent Urinary Tract Infections in Women

Eligibility Criteria

18 Years - 85 Years (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Negative urine culture
  • At least 3 UTI's within 12 months prior to study entry

Exclusion Criteria:

  • Anatomic abnormalities of the urinary tract
  • Use of investigational drugs within 30 days prior to study entry
  • Current use of warfarin
  • Allergy or intolerance of cranberry products
  • > 50 ml of residual urine (measured by US)
  • Use of indwelling catheter
  • uncontrolled diabetes
  • creatinine > 250 mmol/l,
  • Symptomatic vaginitis
  • Pregnant or breastfeeding

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Placebo Comparator

    Arm Label

    Cysticlean arm

    Placebo arm

    Arm Description

    Cysticlean (2 BID for 15 days)

    Placebo (2 BID for 15 days)

    Outcomes

    Primary Outcome Measures

    Effectiveness of the use of Cranberries in the prevention of the recurrent UTIs is women.
    Follow up with urinary cultures will be evaluated for Cranberries affection in UTIs

    Secondary Outcome Measures

    Full Information

    First Posted
    January 13, 2017
    Last Updated
    January 23, 2017
    Sponsor
    University of Thessaly
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03032003
    Brief Title
    Prophylactic Use of Cranberries in Recurrent Bacterial Cystitis in Women
    Official Title
    Prophylactic Use of Cranberries in Recurrent Bacterial Cystitis in Women: A Randomized, Comparative, Study.
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    January 2017
    Overall Recruitment Status
    Unknown status
    Study Start Date
    February 15, 2017 (Anticipated)
    Primary Completion Date
    March 31, 2018 (Anticipated)
    Study Completion Date
    May 31, 2018 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    University of Thessaly

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No

    5. Study Description

    Brief Summary
    To investigate if oral administration of 240mg PAC of cranberries can reduce the number of episodes of acute bacterial cystitis and improve general QoL in women with recurrent bacterial cystitis. In addition, the effect on vagina and rectal flora will studied and the adverse effect profile of the drug will be reported. Women with ≥3 symptomatic episodes of lower UTIs at the previous year will be recruited from the outpatient population who present to their family physician or specialist with symptomatic recurrent UTI. Informed consent will be obtained from all patients and they will be divided in groups according to their age. Urinary culture, vaginal and rectal swab will be taken from all the patients. Antibiotic treatment will be prescribed (using the drug of choice according to the urine culture and the treating physician choice). Subsequently, they will be randomized to receive combined antibiotic treatment with one capsule of Cysticlean 240mg PAC two times per day or antibiotic treatment with placebo. At 14th day post treatment and after a negative urinary culture patients will continue to receive per os, daily, one capsule of Cysticlean 240mg at bed time for 12 months or placebo respectively. Study visits will occur at 3rd, 6th , 9th and 12th month treatment phase. A urine collection, vaginal swabs and rectal swab will be taken at study entry and at the month 3, 6, 9 and 12 visits. Participants will be asked about medication usage, any side effects they may be experiencing at each study visit. If participants develop a UTI at any time during the study, they will be asked to visit the study site within 24 hours.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Recurrent Urinary Tract Infections in Women

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    Participant
    Allocation
    Randomized
    Enrollment
    160 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Cysticlean arm
    Arm Type
    Active Comparator
    Arm Description
    Cysticlean (2 BID for 15 days)
    Arm Title
    Placebo arm
    Arm Type
    Placebo Comparator
    Arm Description
    Placebo (2 BID for 15 days)
    Intervention Type
    Other
    Intervention Name(s)
    Cysticlean
    Intervention Description
    2 BID for 15 days
    Intervention Type
    Other
    Intervention Name(s)
    Placebo
    Intervention Description
    2 BID for 15 days
    Primary Outcome Measure Information:
    Title
    Effectiveness of the use of Cranberries in the prevention of the recurrent UTIs is women.
    Description
    Follow up with urinary cultures will be evaluated for Cranberries affection in UTIs
    Time Frame
    12 months

    10. Eligibility

    Sex
    Female
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    85 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Negative urine culture At least 3 UTI's within 12 months prior to study entry Exclusion Criteria: Anatomic abnormalities of the urinary tract Use of investigational drugs within 30 days prior to study entry Current use of warfarin Allergy or intolerance of cranberry products > 50 ml of residual urine (measured by US) Use of indwelling catheter uncontrolled diabetes creatinine > 250 mmol/l, Symptomatic vaginitis Pregnant or breastfeeding
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Vasileios Tzortzis, Associated Professor
    Email
    tzorvas@otenet.gr
    First Name & Middle Initial & Last Name or Official Title & Degree
    Michael Samarinas, Consultant
    Email
    mikesamih@hotmail.com

    12. IPD Sharing Statement

    Learn more about this trial

    Prophylactic Use of Cranberries in Recurrent Bacterial Cystitis in Women

    We'll reach out to this number within 24 hrs